Positive pre-IND/CTA feedback obtained from several key regulatory agencies for TSHA-102 in Rett syndrome, TSHA-101 in GM2 gangliosidosis and TSHA-118 in CLN1 disease, paving the way for multiple. | August 17, 2021
No Difference in Cognitive Decline After CABG vs PCI medscape.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from medscape.com Daily Mail and Mail on Sunday newspapers.
E-Mail
Mutations in two genetic regions in dogs explain over one third of the risk of developing an aggressive form of hematological cancer, according to a study led by Jacquelyn Evans and Elaine Ostrander at the National Human Genome Research Institute in Maryland, USA and colleagues. The study, which combined multiple sequencing techniques to investigate histiocytic sarcoma in retriever dogs, publishes May 13 in the open-access journal
PLOS Genetics.
Histiocytic sarcoma is an aggressive cancer of immune cells, and although extremely rare in humans, it affects around one-in-five flat-coated retrievers. Genome-wide association surveys of 177 affected and 132 unaffected flat-coated retrievers identified two loci on chromosomes 5 and 19 of the canine genome associated with histiocytic sarcoma. Whole genome, transcriptome, and chromatin immunoprecipitation (CHiP) sequence data revealed that the CFA5 locus contains mutations near a known tumor-suppressor gene, PIK3R6. CFA5 also
Among the most promising therapeutic options for individuals with coronavirus disease 2019 (COVID-19) are monoclonal antibodies (mAbs). In this study, Jones et al . identified, characterized, and tested one such mAb, LY-CoV555, in vitro and in vivo. They found that LY-CoV555 bound to the severe acute respiratory distress syndrome coronavirus-2 (SARS-CoV-2) spike protein and prevented its interaction with angiotensin-converting enzyme 2. Prophylactic treatment with LY-CoV555 protected the upper and lower respiratory tracts of nonhuman primates from becoming infected with SARS-CoV-2. Together, these data support the clinical use of LY-CoV555 for treating patients with COVID-19.
Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) poses a public health threat for which preventive and therapeutic agents are urgently needed. Neutralizing antibodies are a key class of therapeutics that may bridge widespread vaccination campaigns and offer a treatment solution in populations less res
Risk of miscarriage in women with chronic diseases in Norway: A registry linkage study
Maria C. Magnus , Roles Investigation, Methodology, Writing – review & editing
Affiliations Centre for Fertility and Health, Norwegian Institute of Public Health, Oslo, Norway, Department of Clinical Science, University of Bergen, Bergen, Norway, Department of Obstetrics and Gynecology, Haukeland University Hospital, Bergen, Norway ⨯
Knut-Arne Wensaas,
Affiliation Research Unit for General Practice, NORCE Norwegian Research Centre, Bergen, Norway Roles Conceptualization, Investigation, Methodology, Writing – review & editing
Affiliation Epidemiology Branch, National Institute of Environmental Health Sciences, National Institutes of Health, Durham, North Carolina, United States of America ⨯
Siri E. Håberg